Published in Sex Transm Infect on February 01, 2002
Genital human papillomavirus genotypes in northwestern Tanzania. J Clin Microbiol (2003) 1.10
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer (2006) 6.59
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA (2001) 5.99
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med (1999) 2.79
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Strategies for global control of cervical cancer. Int J Cancer (1995) 2.52
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (1986) 2.42
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst (1995) 2.01
BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A (1988) 1.91
Comparison of performances of two commercially available tests, a PCR assay and a ligase chain reaction test, in detection of urogenital Chlamydia trachomatis infection. J Clin Microbiol (1998) 1.85
Chlamydial endometritis. J Clin Pathol (1985) 1.80
Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol (2005) 1.70
Chlamydia trachomatis seroprevalence atlas of Finland 1983-2003. Sex Transm Infect (2007) 1.69
Microbiological and histopathological findings in acute pelvic inflammatory disease. Br J Obstet Gynaecol (1987) 1.65
Serum CA 125 in acute pelvic inflammatory disease. Br J Obstet Gynaecol (1989) 1.62
Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer (2000) 1.58
Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ (1997) 1.55
Antibodies against synthetic peptides react with the second Epstein-Barr virus-associated nuclear antigen. EMBO J (1985) 1.48
No serological evidence for non-sexual spread of HPV16. Lancet (1994) 1.47
Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. Eur J Cancer Clin Oncol (1987) 1.46
A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol (1997) 1.42
Anatomic sites of upper genital tract infection. Obstet Gynecol (1985) 1.41
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer (2011) 1.41
An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology (2004) 1.40
Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis (1998) 1.39
Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA. Int J Cancer (1985) 1.38
Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis (1996) 1.36
Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. Am J Epidemiol (1993) 1.32
HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer (2007) 1.30
HLA DQ alleles and interleukin-10 polymorphism associated with Chlamydia trachomatis-related tubal factor infertility: a case-control study. Hum Reprod (2002) 1.29
Immunoblotting and enzyme-linked immunosorbent assay analysis of serological responses in patients infected with herpes simplex virus types 1 and 2. Intervirology (1985) 1.29
Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst (1997) 1.29
Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol (1999) 1.26
Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer (2007) 1.25
Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Infect Dis (1990) 1.25
Serological evaluation of herpes simplex virus type 1 and type 2 infections in pregnancy. Sex Transm Infect (1999) 1.24
Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol (2001) 1.23
A novel and rapid PCR-based method for genotyping human papillomaviruses in clinical samples. J Clin Microbiol (2000) 1.23
Chlamydial pelvic inflammatory disease. Hum Reprod Update (1997) 1.21
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer (2002) 1.20
Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol (2001) 1.20
A population-based seroepidemiological study of cervical cancer. Cancer Res (1994) 1.17
Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol (1999) 1.16
Identification of human papillomavirus seroconversions. J Gen Virol (1995) 1.14
Unsuitability of bakery work for a person with atopy: a study of 234 bakery workers. Ann Allergy (1979) 1.14
Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis. Epidemiology (1998) 1.13
IgA-induced anaphylactic transfusion reactions: a report of four cases. Blood (1973) 1.12
Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. J Natl Cancer Inst (1999) 1.11
Lymphoblastoid cell lines and Burkitt-lymphoma-derived cell lines differ in the expression of a second Epstein-Barr virus encoded nuclear antigen. Int J Cancer (1986) 1.10
Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol (1996) 1.09
Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int J Cancer (1998) 1.08
Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies--a prospective study. Cancer Causes Control (1993) 1.07
Correlates of the spread of human papillomavirus infection. Cancer Epidemiol Biomarkers Prev (2000) 1.06
Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer (2000) 1.06
A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. Cancer Res (1997) 1.05
Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. Virology (1995) 1.05
Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969-1989. Int J Cancer (1998) 1.04
Down-regulation of the EBV-encoded membrane protein (LMP) in Burkitt lymphomas. Int J Cancer (1987) 1.03
Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J Clin Microbiol (1991) 1.03
Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study. Ann Oncol (2011) 1.03
A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer (1996) 1.03
Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis (1996) 1.03
Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. Cancer Epidemiol Biomarkers Prev (2000) 1.02
Structural analysis of the human papillomavirus type 16-E2 transactivator with antipeptide antibodies reveals a high mobility region linking the transactivation and the DNA-binding domains. Nucleic Acids Res (1991) 1.01
Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. Cancer (1988) 1.01
The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes. J Gen Virol (1995) 1.00
Combined effect of low-penetrant SNPs on breast cancer risk. Br J Cancer (2011) 1.00
Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med (1997) 0.99
Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J Gen Virol (2007) 0.99
A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol (2000) 0.98
Detection of Chlamydia pneumoniae-reactive T lymphocytes in human atherosclerotic plaques of carotid artery. Arterioscler Thromb Vasc Biol (2000) 0.98
Nuclear DNA-binding proteins determined by the Epstein-Barr virus-related simian lymphotropic herpesviruses H. gorilla, H. pan, H. pongo and H. papio. J Gen Virol (1987) 0.97
No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer (1999) 0.97
Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses. J Virol (1991) 0.96
The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. J Eur Acad Dermatol Venereol (2009) 0.95
Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer (1996) 0.95
Cytokine polymorphisms and severity of tubal damage in women with Chlamydia-associated infertility. J Infect Dis (2009) 0.95
Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites. Br J Cancer (2003) 0.95
Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int J Cancer (1990) 0.94